Navigation Links
Women & Infants studying therapies to relieve urinary urge incontinence

Overactive bladder, or the sudden urge to urinate, affects the quality of life of many women. Studies have shown that not all women respond to or can tolerate oral medications and may benefit from other therapies.

Women & Infants Hospital of Rhode Island is conducting a study to compare the effect of two therapies in women who have bothersome urinary urge incontinence after trying other treatments. Patients are currently being enrolled in the ROSETTA Study Reftractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment. The ROSETTA Study is part of the national Pelvic Floor Disorders Network which is funded by the National Institute of Child Health and Development and the Office of Research on Women's Health.

Principal investigator at Women & Infants is Deborah Myers, MD, director of the Division of Urogynecology and Reconstructive Pelvic Surgery at Women & Infants and at The Warren Alpert Medical School of Brown University.

"There are more than 10 million women who suffer from incontinence in America today and more than 50,000 women in Rhode Island alone. That's about one in four between the ages of 30 and 59," said Dr. Myers. "For some women, medications and physical therapy may not help. If we can find another therapy option for these women, we can dramatically impact their quality of life. That's what studies like ROSETTA are all about."

The ROSETTA Study will compare the effect of two therapies in women who have bothersome urinary urge incontinence after trying other treatments. The two new treatments are:

  • Botox, a medication injected into the bladder, or
  • InterStim Therapy, a reversible treatment that uses mild electrical pulses to stimulate nerves going to the bladder (neuromodulation) that influence bladder function.

Women who may be eligible to participate are over 21 years of age, report symptoms of urge incontinence or overactive bladder, experience this leakage two or more times a day, and have tried other treatments including oral medication. Participation will include receiving one of the two procedures and monthly office visits or telephone follow-up for six months and follow-up every three to six months for 24 months.


Contact: Amy Blustein
Women & Infants Hospital

Related medicine news :

1. Women decrease condom use during freshman year of college, study finds
2. Fewer women need repeat breast cancer surgeries with new service at University of Michigan
3. The North American Menopause Society (NAMS) reassures many women
4. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
5. Stem Cell Finding Could Expand Womens Lifetime Supply of Eggs
6. Contraceptives Work Well in Obese Women, But Hormone Levels Lower
7. Citrus Fruits May Lower Womens Stroke Risk
8. Mammograms Can Save Lives of Women in Their 40s: Study
9. Eating Fish May Help Ward Off Colon Polyps in Women
10. Women with rheumatoid arthritis and lupus give birth to fewer children
11. Circulatory Disorder Not Studied Enough in Women, Experts Say
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani ... Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled ... Contact Center solutions targeted to the high-end enterprise contact center marketplace. , Ed ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: